News

Read the latest updates about BioMarin and learn more about our science, our people and the communities we support.

Community

Becky Jackson Curran Advocates for Accessibility and Understanding

July 14, 2026

Community

Why Do I Pheel This Way? Episode 3: Finding Strength Through Sports While Living with Phenylketonuria

June 25, 2026

From Unexpected Turns to Purposeful Impact

June 24, 2026

Stories

All Stories

Community

Becky Jackson Curran Advocates for Accessibility and Understanding

July 14, 2026

Community

Why Do I Pheel This Way? Episode 3: Finding Strength Through Sports While Living with Phenylketonuria

June 25, 2026

From Unexpected Turns to Purposeful Impact

June 24, 2026

Community

Why Do I Pheel This Way? Episode 2 Explores Social Life, Support and Self-Advocacy for Teens with Phenylketonuria

June 11, 2026

Kim Warner Builds Pathways for Early-Career Professionals Seeking Mission-Driven Opportunities

May 29, 2026

Community

Why Do I Pheel This Way? New Video Podcast Series Sheds Light on Navigating Adolescence with Phenylketonuria

May 28, 2026

Press Releases

All Press Releases

U.S. Food and Drug Administration Accepts BioMarin’s Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

July 13, 2026

BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026

June 16, 2026

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

May 20, 2026

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency

May 18, 2026

BioMarin Reports First Quarter 2026 Financial and Operating Results

May 4, 2026

Company Statements

All Company Statements

News

Becky Jackson Curran Advocates for Accessibility and Understanding

Why Do I Pheel This Way? Episode 3: Finding Strength Through Sports While Living with Phenylketonuria

From Unexpected Turns to Purposeful Impact

Stories

Becky Jackson Curran Advocates for Accessibility and Understanding

Why Do I Pheel This Way? Episode 3: Finding Strength Through Sports While Living with Phenylketonuria

From Unexpected Turns to Purposeful Impact

Why Do I Pheel This Way? Episode 2 Explores Social Life, Support and Self-Advocacy for Teens with Phenylketonuria

Kim Warner Builds Pathways for Early-Career Professionals Seeking Mission-Driven Opportunities

Why Do I Pheel This Way? New Video Podcast Series Sheds Light on Navigating Adolescence with Phenylketonuria

Press Releases

U.S. Food and Drug Administration Accepts BioMarin’s Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency

BioMarin Reports First Quarter 2026 Financial and Operating Results

Company Statements

You’re leaving the BioMarin website.

Enter your DIN number